| Balance sheet (USD) | FY 2025 ended Jun 30, 2025 | FY 2024 ended Jun 30, 2024 | FY 2023 ended Jun 30, 2023 | FY 2022 ended Jun 30, 2022 | FY 2021 ended Jun 30, 2021 | FY 2020 ended Jun 30, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 1.56M | 4.80M | 8.15M | 14.07M | 20.52M | 13.71M |
| Total current assets | 1.67M | 4.97M | 8.45M | 14.42M | 20.82M | 13.99M |
| Property, plant and equipment | 6.83M | 7.51M | 8.11M | 8.69M | 9.08M | 9.54M |
| Goodwill and intangibles | 317.0K | 325.3K | 333.6K | 341.8K | 350.1K | 358.4K |
| Total assets | 8.82M | 12.82M | 16.90M | 23.49M | 30.26M | 23.91M |
| Total current liabilities | 1.31M | 1.36M | 534.3K | 412.8K | 351.1K | 2.16M |
| Total liabilities | 1.30M | 1.36M | 2.03M | 412.8K | 351.1K | 2.16M |
| Retained earnings | -148.84M | -139.37M | -131.08M | -122.49M | -114.39M | -105.56M |
| Shareholders' equity | 7.52M | 11.46M | 14.87M | 23.08M | 29.91M | 21.76M |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.